Biopharma companies don’t usually buy experimental drugs that don’t work.
But that’s exactly what CODA Biotherapeutics has done.
On Wednesday, South San Francisco-based CODA announced its acquisition of Attenua, another venture-backed, early-stage biotech company. In exchange for an undisclosed amount, CODA got three of Attenua’s drug candidates. Attenua had hoped they would work as therapies for chronic cough.
About the Author Reprints
